Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 15 de 15 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chao TF, Chiang CE, Chen TJ, Lip GYH, Chen SA. Reassessment of risk for stroke during follow-up of patients with atrial fibrillation. Ann Intern Med 2019:1 de enero. [Ref.ID 102996]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]
4.Tiene citas relacionadas Cita con resumen
5. Cita con resumen
Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7. [Ref.ID 100280]
6.Enlace a cita original Cita con resumen
Anónimo. Riesgos de los AINE en pacientes que reciben tratamiento antitrombótico. Butlletí Groc 2015;28:5-10. [Ref.ID 99839]
7. Cita con resumen
Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen H, Larsen TB, Lip GYH. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015;314:8 de septiembre. [Ref.ID 99418]
8. Cita con resumen
Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM. Oral anticoagulant prescription in patients with atrial fibrillation and a low risk of thromboembolism: insights from the NCDR PINNACLE registry. JAMA Intern Med 2015;175:1062-5. [Ref.ID 99111]
9.Tiene citas relacionadas Cita con resumen
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 2015;65:635-42. [Ref.ID 99046]
10.Tiene citas relacionadas Cita con resumen
Singer DE, Ezekowitz MD. Adding rigor to stroke risk prediction in atrial fibrillation. J Am Coll Cardiol 2015;65:233-5. [Ref.ID 99045]
11.Tiene citas relacionadas Cita con resumen
Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225-32. [Ref.ID 99044]
12.Tiene citas relacionadas Cita con resumen
Fleischmann KE. Should we anticoagulate patients with CHA2DS2-VASc scores of 1? . Journal Watch 2015:7 de mayo. [Ref.ID 99040]
13. Cita con resumen
O'Brien EC, Kim S, Hess PL, Kowey PR, Fonarow GC, Piccini JP, Peterson ED. Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation. JAMA Intern Med 2015;175:848-50. [Ref.ID 98945]
14. Cita con resumen
Lip GYH, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-94. [Ref.ID 98892]
Seleccionar todas
 
 1 a 15 de 15